Inhaled PH-COPD Drug Fails to Improve Walking Distance
A new clinical trial shows this inhaled treatment did not improve exercise capacity for patients with PH-COPD.
Updated on Oct. 21, 2026 in Asthma
Live Poll
Do you believe experimental lung therapies should be prioritized even if early trials show limited benefits?
An inhaled drug designed to treat pulmonary hypertension in patients with COPD failed to show a statistically significant benefit in a recent clinical trial. The study found no meaningful improvement in walking distance compared to a placebo over 24 weeks.
Why it matters
This trial highlights the ongoing challenge of identifying effective treatments for pulmonary hypertension in patients who also have COPD. The results provide important evidence for researchers as they work to determine which health outcomes may be most relevant for this patient population in future studies.
This Phase 2a randomized trial followed 128 patients for 24 weeks to assess the efficacy of inhaled frespaciguat. The treatment failed to meet its primary endpoint of significantly improving 6-minute walk distance compared to placebo.
The players
Medical University of Graz
An Austrian research institution home to investigators specializing in pulmonary hypertension and respiratory health.
The details
Patients in the study received either a 380 µg dose of inhaled frespaciguat or a placebo once daily via a dry-powder inhaler. Researchers evaluated the treatment's impact on pulmonary vascular resistance and exercise capacity in individuals with both chronic obstructive pulmonary disease and pulmonary hypertension. While the treatment was not effective for the primary walking distance outcome, investigators noted that clinical worsening events were primarily driven by COPD exacerbations rather than the study intervention.
Timeline
October 18-21, 2026: Results were presented at the CHEST 2026 Annual Meeting.
Week 24: Final assessment of 6-minute walk distance was conducted.
Health Landscape
This study is part of an ongoing effort to address the complex intersection of pulmonary hypertension and chronic obstructive pulmonary disease. It contributes to the evolving medical literature on how targeted inhalants might interact with existing respiratory limitations.
Patients managing both COPD and pulmonary hypertension should continue to follow their current treatment plans as prescribed by their medical team. The significance of these findings for individual care should be discussed during your next appointment with a pulmonologist or cardiologist.
The takeaway
This study clarifies the current limitations of frespaciguat for improving exercise capacity in those with PH-COPD. Patients should maintain open communication with their physicians regarding any concerns about exercise tolerance or symptoms of clinical worsening.
Further reading
For broader context on current approaches to managing complex airway and lung conditions, visit Asthma.
More information
For detailed data from the study, review the complete trial study information.
Live Poll
Do you believe experimental lung therapies should be prioritized even if early trials show limited benefits?
